secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0001213900-22-076880
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma provides pipeline update, cites $12M cash and zero debt
-------------------------------------------------------------------

- Cash over $12M, no debt, listed on Nasdaq; pursuing 505(b)(2) pathway for several assets.
- SP-26 (ketamine for fibromyalgia) preparing pre-IND submission; safety evaluation underway.
- SPU-16 (MS) and SPU-21 (RA) under license from University of Maryland; SPU-21 inhibited arthritis in preclinical model.
- SPC-14 (Alzheimer's) showed proof-of-concept in mouse model; SPC-15 (PTSD) under Columbia option.
- Sponsored clinical study with UCSF on psilocybin's anti-inflammatory effects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390022076880/0001213900-22-076880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390022076880/ea169527-8k_silopharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-076880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer